Johnson & Johnson begins final phase of single-shot COVID-19 vaccine study
Drug manufacturer Johnson & Johnson has launched a final phase 3 study of its COVID-19 vaccine candidate, seeking out 60,000 participants across the United States, South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. It is administered as a single dose, unlike some of the other leading candidates which are delivered in two doses. Pfizer, Moderna and AstraZeneca are among the manufacturers that also have candidates in late stage trials.
Published: September 23, 2020